Novel test identifies patients most likely to benefit from ALK inhibition therapy
Approximately one in 20 patients with non-small cell lung carcinoma (NSCLC) has chromosomal aberrations targeting the anaplastic lymphoma kinase (ALK) gene. This has considerable implications for treatment because these patients ...
Medical research
Dec 12, 2012 |
not rated yet |
0
|
Blood levels of immune protein predict risk in Hodgkin disease
Blood levels of an immunity-related protein, galectin-1, in patients with newly diagnosed Hodgkin lymphoma reflected the extent of their cancer and correlated with other predictors of outcome, scientists reported at the American ...
Cancer
Dec 10, 2012 |
not rated yet |
0
Novel drug therapy targets aggressive form of non-Hodgkin's lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma and the seventh most frequently diagnosed cancer. The most chemotherapy resistant form of DLBCL, called activated B-cell – DLBCL ...
Cancer
Dec 10, 2012 |
not rated yet |
0
|
Bone marrow biopsy adds little to PET/CT staging of Hodgkin's
(HealthDay)—For patients with treatment-naive Hodgkin's lymphoma (HL) staged using [18F]fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT), routine bone marrow biopsy (BMB) has little or no ther ...
Cancer
Nov 15, 2012 |
not rated yet |
0
Genome sequencing of Burkitt Lymphoma reveals unique mutation
In the first broad genetic landscape mapped of a Burkitt lymphoma tumor, scientists at Duke Medicine and their collaborators identified 70 mutations, including several that had not previously been associated with cancer and ...
Genetics
Nov 12, 2012 |
5 / 5 (1) |
0
|
Triptorelin doesn't avert early ovarian failure in lymphoma
(HealthDay)—Treatment of lymphoma patients with the gonadotropin-releasing hormone agonist (GnRHa) triptorelin plus norethisterone does not reduce the rate of chemotherapy-induced premature ovarian failure ...
Cancer
Nov 07, 2012 |
not rated yet |
0
Scientists harness immune system to prevent lymphoma relapse
UK scientists hope that lymphoma patients could benefit from a new drug that triggers the cancer-fighting properties of the body's own immune system, after highly promising early laboratory results.
Cancer
Oct 18, 2012 |
not rated yet |
0
|
Of mice and men
The use of carefully chosen animal models often underlies crucial medical advances. A perfect example is provided by the recent demonstration that a known drug, imatinib, can be used to treat a rare but ...
Cancer
Oct 15, 2012 |
not rated yet |
0
HIV status doesn't influence Hodgkin's lymphoma outcome
(HealthDay)—Despite more extensive disease and more adverse prognostic factors, HIV-positive patients with Hodgkin's lymphoma (HL) do not have worse outcomes when treated with doxorubicin, bleomycin, vinblastine, ...
Cancer
Oct 11, 2012 |
not rated yet |
0
Women respond better to the treatment of lymph gland cancer with antibodies than men
(Medical Xpress)—Women respond much better than men to the treatment of chronic follicular lymphoma with a monoclonal antibody that targets CD20 (rituximab). These are the findings of a multi-centre, Austria-wide ...
Cancer
Oct 10, 2012 |
5 / 5 (1) |
0
Melanoma up to 2.5 times likelier to strike transplant, lymphoma patients
Melanoma is on the rise nationally, and transplant recipients and lymphoma patients are far likelier than the average person to get that form of skin cancer and to die from it, a Mayo Clinic review has found. That is because ...
Cancer
Oct 03, 2012 |
not rated yet |
0
Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-positive lung cancer
The results of a new phase III trial show that crizotinib, a targeted therapy, is a more effective treatment than standard chemotherapy for patients with advanced, ALK-positive lung cancer, researchers said at the ESMO 2012 ...
Cancer
Sep 30, 2012 |
not rated yet |
0
Watch-and-wait OK in low-tumor burden follicular lymphoma
(HealthDay)—An initial watch-and-wait strategy does not have a detrimental effect on the freedom from treatment failure (FFTF) or overall survival rate in selected patients with low-tumor burden follicular ...
Cancer
Sep 26, 2012 |
5 / 5 (1) |
0
Mutation ID'd in Waldenstrom's macroglobulinemia
(HealthDay)—MYD88 L265P is a common, recurring mutation in patients with Waldenström's macroglobulinemia, according to a study published in the Aug. 30 issue of the New England Journal of Medicine.
Cancer
Aug 30, 2012 |
not rated yet |
0
Many options, good outcomes, for early-stage follicular lymphoma
(Medical Xpress) -- A University of Rochester Medical Center study challenges treatment guidelines for early stage follicular lymphoma, concluding that six different therapies can bring a remission, particularly if the patient ...
Cancer
Aug 21, 2012 |
not rated yet |
0
|
